What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?
The share price of JAGSNPHARM as on 15th September 2025 is ₹250.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are- Past 1 week: -0.20%
- Past 1 month: -4.22%
- Past 3 months: 7.36%
- Past 6 months: 21.67%
- Past 1 year: 52.54%
- Past 3 years: 61.48%
- Past 5 years: 1509.40%
What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
The peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) include:What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 1.04.What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1601.82 Cr as of 15th September 2025.What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹328.04 and the 52-week low is ₹153.10.What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?
The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 28.93. The P/B (price-to-book) ratio is 6.68.Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?
You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jagsonpal Pharmaceuticals Ltd
JAGSNPHARM Share Price
250.104.03% (+9.70)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
JAGSNPHARM Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JAGSNPHARM Performance & Key Metrics
JAGSNPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 26.34 | 6.68 | 1.04% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.36 | 5.90 | 0.58% |
JAGSNPHARM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
JAGSNPHARM Company Profile
Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.
SUNPHARMA
PE Ratio
35.49
35.49
1Y Return
14.01%
14.01%
Buy Reco %
86.11
86.11
CIPLA
PE Ratio
24.12
24.12
1Y Return
6.70%
6.70%
Buy Reco %
66.67
66.67
TORNTPHARM
PE Ratio
63.15
63.15
1Y Return
2.25%
2.25%
Buy Reco %
76.00
76.00
DRREDDY
PE Ratio
19.38
19.38
1Y Return
2.15%
2.15%
Buy Reco %
40.00
40.00
MANKIND
PE Ratio
53.48
53.48
1Y Return
5.26%
5.26%
Buy Reco %
81.25
81.25
JAGSNPHARM Sentiment Analysis
JAGSNPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
JAGSNPHARM Stock Summary · July 2025
The company demonstrated robust revenue growth of 23% year-over-year, bolstered by strong brand equity and a strategic focus on niche molecules, despite facing pricing pressures on certain products. While operational stability and margin management remain priorities, the recent termination of the CFO raised governance concerns. The management is committed to enhancing field force productivity and reducing attrition, recognizing its critical role in driving business growth. Additionally, the MySakhi initiative reflects a dedication to social responsibility, empowering women through health and education programs. With a solid financial position and no debt, the company is well-positioned for strategic acquisitions, although it remains cautious in a challenging market environment.
JAGSNPHARM Stock Growth Drivers
JAGSNPHARM Stock Growth Drivers
6Strong Financial Performance
Jagsonpal Pharmaceuticals Limited reported a robust financial performance for Q1 FY '26, with a 23%
Brand Strength and Market Position
The company has demonstrated strong brand performance, with the top 15 brands accounting for two-thirds
JAGSNPHARM Stock Challenges
JAGSNPHARM Stock Challenges
5Decline in Sales and Market Position
The company has experienced a significant decline in sales for its Dydrogestorone product, dropping from
Thin Margins and Competitive Strategy
The company is currently selling Dydrogestorone at thin margins, which has led to a lack
JAGSNPHARM Forecast
JAGSNPHARM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
JAGSNPHARM
JAGSNPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
JAGSNPHARM Income Statement
JAGSNPHARM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 157.14 | 126.99 | 168.26 | 161.10 | 192.34 | 221.01 | 242.44 | 217.98 | 300.27 | 315.65 | ||||||||||
Raw Materials | 67.34 | 65.19 | 53.43 | 54.94 | 75.50 | 83.35 | 88.04 | 76.08 | 98.56 | 228.06 | ||||||||||
| Power & Fuel Cost | 2.12 | 1.00 | 1.41 | 0.64 | 0.52 | 0.47 | 0.29 | 0.17 | 0.19 | |||||||||||
| Employee Cost | 40.95 | 41.88 | 46.61 | 50.37 | 53.98 | 57.68 | 65.18 | 62.09 | 70.93 | |||||||||||
| Selling & Administrative Expenses | 30.19 | 27.56 | 32.23 | 38.34 | 31.88 | 42.50 | 41.66 | 40.80 | 48.54 | |||||||||||
| Operating & Other expenses | -2.50 | 2.01 | 23.81 | 5.75 | 6.99 | 8.56 | 10.85 | 6.50 | 3.09 | |||||||||||
EBITDA | 19.04 | -10.65 | 10.77 | 11.06 | 23.47 | 28.45 | 36.42 | 32.34 | 78.96 | 87.59 | ||||||||||
| Depreciation/Amortization | 1.99 | 0.32 | 1.02 | 1.13 | 1.09 | 1.53 | 1.21 | 1.66 | 8.13 | 9.41 | ||||||||||
| PBIT | 17.05 | -10.97 | 9.75 | 9.93 | 22.38 | 26.92 | 35.21 | 30.68 | 70.83 | 78.18 | ||||||||||
| Interest & Other Items | 2.64 | 0.66 | 0.75 | 0.51 | 0.51 | 0.29 | 0.41 | 0.81 | 0.96 | 1.00 | ||||||||||
| PBT | 14.41 | -11.63 | 9.00 | 9.42 | 21.87 | 26.63 | 34.80 | 29.87 | 69.87 | 77.18 | ||||||||||
| Taxes & Other Items | 2.53 | -0.08 | 1.78 | 1.54 | 4.82 | 7.78 | 8.09 | 7.41 | 14.50 | 16.36 | ||||||||||
| Net Income | 11.88 | -11.55 | 7.22 | 7.88 | 17.05 | 18.85 | 26.71 | 22.46 | 55.37 | 60.82 | ||||||||||
| EPS | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.41 | 8.36 | 9.16 | ||||||||||
| DPS | 0.04 | 0.04 | 0.10 | 0.20 | 0.40 | 1.60 | 2.00 | 2.00 | 2.50 | 2.00 | ||||||||||
| Payout ratio | 0.02 | — | 0.09 | 0.17 | 0.15 | 0.56 | 0.49 | 0.59 | 0.30 | 0.22 |
JAGSNPHARM Company Updates
FY 2026FY 2026
Investor Presentation
Jul 26PDF
JAGSNPHARM Stock Peers
JAGSNPHARM Past Performance & Peer Comparison
JAGSNPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 28.93 | 6.68 | 1.04% |
| Sun Pharmaceutical Industries Ltd | 35.49 | 5.35 | 0.99% |
| Cipla Ltd | 24.12 | 4.06 | 1.02% |
| Torrent Pharmaceuticals Ltd | 63.15 | 15.90 | 0.90% |
JAGSNPHARM Stock Price Comparison
Compare JAGSNPHARM with any stock or ETFCompare JAGSNPHARM with any stock or ETF
JAGSNPHARM
JAGSNPHARM Holdings
JAGSNPHARM Shareholdings
JAGSNPHARM Promoter Holdings Trend
JAGSNPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JAGSNPHARM Institutional Holdings Trend
JAGSNPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding History
JAGSNPHARM Shareholding History
Foreign Institutions
smallcases containing JAGSNPHARM stock
smallcases containing JAGSNPHARM stock
Looks like this stock is not in any smallcase yet.
JAGSNPHARM Events
JAGSNPHARM Events
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.04%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.36 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.04%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.36 every year
JAGSNPHARM Upcoming Dividends
JAGSNPHARM Upcoming Dividends
No upcoming dividends are available
JAGSNPHARM Past Dividends
JAGSNPHARM Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateAug 21, 2023
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 21, 2023
Cash Dividend
Ex DateEx DateOct 29, 2021
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Oct 29, 2021
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2021
JAGSNPHARM Stock News & Opinions
JAGSNPHARM Stock News & Opinions
Articles & Videos
Corporate
Jagsonpal Pharmaceuticals allots 66,000 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 66,000 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employees of the Company, upon exercise of vested options. These shares shall rank Pari-passu with the existing equity shares of the Company, in all respects. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,31,30,508 (constituting of 6,65,65,254 equity shares of Rs. 2/- each) to Rs. 13,32,62,508 (constituting of 6,66,31,254 equity shares of Rs. 2/- each).Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals AGM scheduled
Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting(AGM) of the company will be held on 24 September 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals fixes record for dividend
Jagsonpal Pharmaceuticals has fixed 12 September 2025 as record date for determining entitlement of Members to dividend for the financial year ended 31 March 2025. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 102.63% in the June 2025 quarter
Net profit of Jagsonpal Pharmaceuticals rose 102.63% to Rs 10.80 crore in the quarter ended June 2025 as against Rs 5.33 crore during the previous quarter ended June 2024. Sales rose 23.06% to Rs 75.61 crore in the quarter ended June 2025 as against Rs 61.44 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales75.6161.44 23 OPM %18.7916.68 - PBDT16.7911.47 46 PBT14.4410.40 39 NP10.805.33 103 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to announce Quarterly Result
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 July 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 53,000 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 53,000 equity shares under ESOP on 11 June 2025. With this allotment, the paid up equity share capital has increased from Rs. 13,29,46,960 (constituting of 6,64,73,480 equity shares of Rs. 2/- each) to Rs. 13,30,52,960 (constituting of 6,65,26,480 equity shares of Rs. 2/- each).Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Board of Jagsonpal Pharmaceuticals recommends final dividend
Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 6 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 125%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 85.35% in the March 2025 quarter
Net profit of Jagsonpal Pharmaceuticals rose 85.35% to Rs 6.58 crore in the quarter ended March 2025 as against Rs 3.55 crore during the previous quarter ended March 2024. Sales rose 34.65% to Rs 58.56 crore in the quarter ended March 2025 as against Rs 43.49 crore during the previous quarter ended March 2024. For the full year,net profit rose 146.48% to Rs 55.36 crore in the year ended March 2025 as against Rs 22.46 crore during the previous year ended March 2024. Sales rose 28.76% to Rs 268.72 crore in the year ended March 2025 as against Rs 208.70 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales58.5643.49 35 268.72208.70 29 OPM %14.896.12 -19.0011.05 - PBDT11.234.93 128 58.3031.53 85 PBT8.924.53 97 50.1729.87 68 NP6.583.55 85 55.3622.46 146 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to announce Quarterly Result
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 39,850 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 39,850 equity shares under ESOP. With this allotment, the paid up equity share capital has increased to Rs. 13,28,76,960 (constituting of 6,64,38,480 equity shares of Rs. 2/- each).Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.26%, vs industry avg of 9.99%
Over the last 5 years, market share increased from 0.06% to 0.07%
Over the last 5 years, net income has grown at a yearly rate of 47.69%, vs industry avg of 20.01%